Change in blood tacrolimus concentration by fluctuation of renal function in a bone marrow transplant patient

被引:0
作者
Masaki Sumi
Hiroki Konishi
Yoshihiro Ikuno
Nobuo Hoshino
Tokuzo MiNouchi
Akira Yamaji
机构
[1] Shiga University of Medical Science,Department of Hospital Pharmacy
[2] Osaka Ohtani University,Laboratory of Clinical Pharmacy and Therapeutics, Faculty of Pharmacy
来源
European Journal of Drug Metabolism and Pharmacokinetics | 2009年 / 34卷
关键词
Tacrolimus; renal function; pharmacokinetics; bone marrow transplantation;
D O I
暂无
中图分类号
学科分类号
摘要
The authors report a case showing a marked change in blood tacrolimus concentration due to modification of renal function in a bone marrow transplant recipient. Blood tacrolimus concentration was well controlled after transplantation, but an approximately threefold increase in the concentration was observed on day 10 even though the dosage was unchanged. Although there were no pronounced changes in hepatic enzyme activities in serum, marked elevations of renal function test values were noted; concentrations of serum creatinine (SCr) and blood urea nitrogen (BUN) were increased by more than 300% from the original levels. The tacrolimus concentration was gradually decreased by the dose reduction, but the dose-adjusted tacrolimus blood concentration (C/D) was increased contrary to the decreased tacrolimus concentration. The C/D of tacrolimus also began to decline from several days after the recovery of Scr and BUN levels and returned to the basal level. Our finding suggests that renal function has a significant effect on the pharmacokinetic disposition of tacrolimus, although this agent is almost completely eliminated by hepatic metabolism. Careful attention should be paid to alteration in tacrolimus blood concentration, especially when renal function fluctuates during post-transplant immunosuppressive therapy.
引用
收藏
页码:201 / 204
页数:3
相关论文
共 107 条
  • [1] Mourad M.(2008)Biotransformation enzymes and drug transporters pharmacogenetics in relation to immunosuppressive drugs: impact on pharmacokinetics and clinical outcome Trans-plantation 85 S19-24
  • [2] Wallemacq P.(2002)Mechanisms of clinically relevant drug interactions associated with tacrolimus Clin. Pharmacokinet. 41 813-851
  • [3] De Meyer M.(2004)Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation Clin Pharmacokinet. 43 623-653
  • [4] Malaise J.(2006)Role of P-glycoprotein in statin drug interactions Pharmacotherapy 11 1601-1607
  • [5] De Pauw L.(1993)Pharmacokinetics of fluconazole in normal volunteers Chemotherapy 39 6-12
  • [6] Eddour DC(1994)Fluconazole therapy in transplant recipients receiving FK506 Transplantation 57 1521-1535
  • [7] Goffin E.(2000)Pharmacokinetics and bioavailability of tacrolimus in rats with experimental renal dysfunction J. Pharm. Pharmacol. 52 1467-1472
  • [8] Lerut J.(2002)Evaluation of increased bioavailability of tacrolimus in rats with experimental renal dysfunction J. Pharm. Pharmacol. 54 65-70
  • [9] Haufroid V.(1992)The effect of bile duct ligation and bile diversion on FK506 pharmacokinetics in dogs Transplantation 53 722-725
  • [10] Christians U.(2002)Effect of bile flow on the absorption of tac-rolimus in liver allograft transplantation Transplant. Proc 34 1544-1545